Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
disease (MRD) following treatment for solid tumors predicts relapse. These results suggest …
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer
Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial
Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …
Circulating tumor DNA and liquid biopsy in oncology
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
Contemporary radiotherapy: present and future
Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …
continues to have a key role across the disease spectrum in nearly every cancer. However …
Circulating tumor DNA minimal residual disease detection of non–small-cell lung cancer treated with curative intent
B Pellini, AA Chaudhuri - Journal of Clinical Oncology, 2022 - ascopubs.org
Circulating tumor DNA (ctDNA) minimal residual disease (MRD) is a powerful biomarker
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …
with the potential to improve survival outcomes for non–small-cell lung cancer (NSCLC) …
Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer
Importance Adjuvant chemotherapy in patients with stage III colon cancer prevents
recurrence by eradicating minimal residual disease. However, which patients remain at high …
recurrence by eradicating minimal residual disease. However, which patients remain at high …
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent
treatment strongly predicts recurrence in multiple tumor types, but whether further treatment …
treatment strongly predicts recurrence in multiple tumor types, but whether further treatment …
The potential of liquid biopsy in the management of cancer patients
A Markou, E Tzanikou, E Lianidou - Seminars in cancer biology, 2022 - Elsevier
Over the last decade, liquid biopsy has gained much attention as a powerful tool in
personalized medicine, since it enables monitoring cancer evolution and follow-up of cancer …
personalized medicine, since it enables monitoring cancer evolution and follow-up of cancer …